REGENXBIO (NASDAQ:RGNX) Upgraded by Zacks Investment Research to Buy

0
47

REGENXBIO stock has undergone multiple analysts rating changes in the recent past.  REGENXBIO Upgraded by Zacks Investment Research on 10/20/2021. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.

Shares of REGENXBIO traded down -$0.68 on Tuesday, reaching $34.70. 0 shares of the stock traded hands, compared to its average volume of 620656. Shares of REGENXBIO were trading at $34.70 on Tuesday. The firm’s 50 day moving average is $35.96 and its 200 day moving average is $37.80.REGENXBIO has a 12 month low of $34.59 and a 12 month high of $50.26. While on yearly highs and lows, REGENXBIO’s today has traded high as $35.94 and has touched $34.59 on the downward trend. See More Analyst Rating at: RATING

REGENXBIO Earnings and What to expect: 

REGENXBIO last issued its quarterly earnings results on August 9th, 2021. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.08) by $0.28. The business had revenue of $22.04 million for the quarter, compared to analysts’ expectations of $21.17 million. Its revenue for the quarter was up 33.0% on a year-over-year basis. REGENXBIO has generated ($2.98) earnings per share over the last year (($3.57) diluted earnings per share). Earnings for REGENXBIO are expected to decrease in the coming year, from ($2.88) to ($4.06) per share. REGENXBIO has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, November 3rd, 2021 based off prior year’s report dates.

Earnings for REGENXBIO are expected to decrease in the coming year, from ($2.88) to ($4.06) per share. The P/E ratio of REGENXBIO is -9.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of REGENXBIO is -9.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. REGENXBIO has a P/B Ratio of 3.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

REGENXBIO (NASDAQ:RGNX) Moving Average Technical Analysis

5 day Moving Average is $35.57 And 5 day price change is -$1.26 (-3.50%)  with average volume for 5 day average is 261,080. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $37.38 and 20 day price change is -$9.53 (-21.55%) and average 20 day moving volume is 528,035. 50 day moving average is $35.96  and 50 day price change is $2.20 ( 6.77%)  and with average volume for 50 days is : 534,336. 200 day moving average is $37.80  and 200 day price change is -$10.27 (-22.84%)  and with average volume for 200 days is : 421,540.

Other owners latest trading in REGENXBIO :

  • On 10/19/2021 shares held by Assenagon Asset Management S.A. were 137,753 which equates to market value of $5.78M and appx 0.00% owners of REGENXBIO
  • On 10/12/2021 shares held by Koshinski Asset Management Inc. were 600 which equates to market value of $25K and appx 0.00% owners of REGENXBIO
  • On 10/12/2021 shares held by Louisiana State Employees Retirement System were 18,100 which equates to market value of $0.76M and appx 0.00% owners of REGENXBIO
  • In total Institutional ownership equates to Institutional Ownership Percentage: 77.85% for REGENXBIO

See More Analyst Rating at: RATING